Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebicorvir Combination Regimens in Chronic Hepatitis B (Phase 2a)
2020-005766-34Phase 2Terminated
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Apr 2021
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vebicorvir and imdusiran in Chronic Hepatitis B (CHB), sponsored by Assembly Biosciences, Inc. Primary endpoint: Safety and tolerability. Started Apr 2021; status: terminated.
02
Drugs
vebicorvirimdusiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2020-005766-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005766-34.